Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Dow
US Department of Justice
Moodys
Merck
Colorcon
Healthtrust
Baxter
Harvard Business School

Generated: November 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020103

« Back to Dashboard

NDA 020103 describes ZOFRAN, which is a drug marketed by Novartis Pharms Corp and Glaxosmithkline and is included in five NDAs. It is available from two suppliers. Additional details are available on the ZOFRAN profile page.

The generic ingredient in ZOFRAN is ondansetron. There are twenty-eight drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the ondansetron profile page.
Summary for 020103
Tradename:ZOFRAN
Applicant:Novartis Pharms Corp
Ingredient:ondansetron hydrochloride
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020103
Suppliers and Packaging for NDA: 020103
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103 NDA Novartis Pharmaceuticals Corporation 0078-0675 0078-0675-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0675-15)
ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103 NDA Novartis Pharmaceuticals Corporation 0078-0676 0078-0676-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0676-15)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 4MG BASE
Approval Date:Dec 31, 1992TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 8MG BASE
Approval Date:Dec 31, 1992TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 24MG BASE
Approval Date:Aug 27, 1999TE:ABRLD:Yes

Expired US Patents for NDA 020103

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-002 Dec 31, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-001 Dec 31, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-001 Dec 31, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-003 Aug 27, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-003 Aug 27, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-002 Dec 31, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Federal Trade Commission
Accenture
Medtronic
Queensland Health
Cipla
AstraZeneca
QuintilesIMS
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.